Login to Your Account

Other news to note

Thursday, July 10, 2014
Lightlake Therapeutics Inc., of London, signed an agreement with a commercial contract manufacturer that will produce its early stage naloxone-based opioid overdose reversal treatment and has sufficient capacity to carry it through commercialization.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription